膀胱癌中的代谢组学：一项系统综述。
Metabolomics in bladder cancer: a systematic review.
作者信息
Cheng Yidong, Yang Xiao, Deng Xiaheng, Zhang Xiaolei, Li Pengchao, Tao Jun, Qin Chao, Wei Jifu, Lu Qiang
机构信息
Department of Urology, The First Affiliated Hospital of Nanjing Medical University Nanjing, China.
Research Division of Clinical Pharmacology, The First Affiliated Hospital of Nanjing Medical University Nanjing, China.
出版信息
Int J Clin Exp Med. 2015 Jul 15;8(7):11052-63. eCollection 2015.
Abstract
Bladder cancer (BC) is the most common urological malignancy. Early diagnosis of BC is crucial to improve patient outcomes. Currently, metabolomics is a potential technique that can be used to detect BC. We reviewed current publications and synthesised the findings on BC and metabolomics, i.e. metabolite upregulation and downregulation. Fourteen metabolites (lactic acid, leucine, valine, phenylalanine, glutamate, histidine, aspartic acid, tyrosine, serine, uracil, hypoxanthine, carnitine, pyruvic acid and citric acid) were identified as potential biomarkers for BC. In conclusion, this systematic review presents new opportunities for the diagnosis of BC.
摘要
膀胱癌（BC）是最常见的泌尿系统恶性肿瘤。膀胱癌的早期诊断对于改善患者预后至关重要。目前，代谢组学是一种可用于检测膀胱癌的潜在技术。我们回顾了当前的出版物，并综合了关于膀胱癌和代谢组学的研究结果，即代谢物的上调和下调。十四种代谢物（乳酸、亮氨酸、缬氨酸、苯丙氨酸、谷氨酸、组氨酸、天冬氨酸、酪氨酸、丝氨酸、尿嘧啶、次黄嘌呤、肉碱、丙酮酸和柠檬酸）被确定为膀胱癌的潜在生物标志物。总之，本系统综述为膀胱癌的诊断提供了新的机会。
相似文献
1
Metabolomics in bladder cancer: a systematic review.
Int J Clin Exp Med. 2015 Jul 15;8(7):11052-63. eCollection 2015.
2
Metabolomics for the diagnosis of bladder cancer: A systematic review.
Asian J Urol. 2024 Apr;11(2):221-241. doi: 10.1016/j.ajur.2022.11.005. Epub 2023 Sep 12.
3
Metabolomics in the development and progression of rheumatoid arthritis: A systematic review.
Joint Bone Spine. 2020 Oct;87(5):425-430. doi: 10.1016/j.jbspin.2020.05.005. Epub 2020 May 27.
4
Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer.
Front Oncol. 2018 Nov 2;8:494. doi: 10.3389/fonc.2018.00494. eCollection 2018.
5
Volatile metabolomic signature of bladder cancer cell lines based on gas chromatography-mass spectrometry.
Metabolomics. 2018 Apr 17;14(5):62. doi: 10.1007/s11306-018-1361-9.
6
Biomarkers in bladder cancer: A metabolomic approach using in vitro and ex vivo model systems.
Int J Cancer. 2016 Jul 15;139(2):256-68. doi: 10.1002/ijc.30016. Epub 2016 Feb 23.
7
Discovery of urine biomarkers for bladder cancer via global metabolomics.
Biomarkers. 2016 Nov;21(7):578-88. doi: 10.3109/1354750X.2016.1171903. Epub 2016 May 2.
8
The association between plasma metabolites and future risk of all-cause mortality.
J Intern Med. 2022 Nov;292(5):804-815. doi: 10.1111/joim.13540. Epub 2022 Jul 26.
9
Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach.
J Chromatogr A. 2013 Nov 29;1318:163-70. doi: 10.1016/j.chroma.2013.10.002. Epub 2013 Oct 4.
10
Quantitative analysis of amino acids and acylcarnitines combined with untargeted metabolomics using ultra-high performance liquid chromatography and quadrupole time-of-flight mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Aug 1;1027:40-9. doi: 10.1016/j.jchromb.2016.05.006. Epub 2016 May 14.
引用本文的文献
1
Targeting ketone body metabolism in mitigating gemcitabine resistance.
JCI Insight. 2024 Dec 20;9(24):e177840. doi: 10.1172/jci.insight.177840.
2
Metabolomics for the diagnosis of bladder cancer: A systematic review.
Asian J Urol. 2024 Apr;11(2):221-241. doi: 10.1016/j.ajur.2022.11.005. Epub 2023 Sep 12.
3
Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review.
Int J Mol Sci. 2024 Mar 15;25(6):3347. doi: 10.3390/ijms25063347.
4
Metabolomic profiling of human bladder tissue extracts.
Metabolomics. 2024 Jan 24;20(1):14. doi: 10.1007/s11306-023-02076-w.
5
Rapid and precise detection of cancers via label-free SERS and deep learning.
Anal Bioanal Chem. 2023 Jul;415(17):3449-3462. doi: 10.1007/s00216-023-04730-7. Epub 2023 May 17.
6
Performance comparison of three scaling algorithms in NMR-based metabolomics analysis.
Open Life Sci. 2023 Mar 27;18(1):20220556. doi: 10.1515/biol-2022-0556. eCollection 2023.
7
New bladder cancer non-invasive surveillance method based on voltammetric electronic tongue measurement of urine.
iScience. 2022 Aug 4;25(9):104829. doi: 10.1016/j.isci.2022.104829. eCollection 2022 Sep 16.
8
Toward a SERS Diagnostic Tool for Discrimination between Cancerous and Normal Bladder Tissues via Analysis of the Extracellular Fluid.
ACS Omega. 2022 Mar 17;7(12):10539-10549. doi: 10.1021/acsomega.2c00058. eCollection 2022 Mar 29.
9
Pre- and Post-Resection Urine Metabolic Profiles of Bladder Cancer Patients: Results of Preliminary Studies on Time Series Metabolomics Analysis.
Cancers (Basel). 2022 Feb 25;14(5):1210. doi: 10.3390/cancers14051210.
10
Multi Platforms Strategies and Metabolomics Approaches for the Investigation of Comprehensive Metabolite Profile in Dogs with Infection.
Int J Mol Sci. 2022 Jan 29;23(3):1575. doi: 10.3390/ijms23031575.
本文引用的文献
1
Diagnosis of bladder cancer and prediction of survival by urinary metabolomics.
Oncotarget. 2014 Mar 30;5(6):1635-45. doi: 10.18632/oncotarget.1744.
2
Nucleotide metabolism, oncogene-induced senescence and cancer.
Cancer Lett. 2015 Jan 28;356(2 Pt A):204-10. doi: 10.1016/j.canlet.2014.01.017. Epub 2014 Jan 29.
3
Low- and high-grade bladder cancer determination via human serum-based metabolomics approach.
J Proteome Res. 2013 Dec 6;12(12):5839-50. doi: 10.1021/pr400859w. Epub 2013 Nov 18.
4
Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach.
J Chromatogr A. 2013 Nov 29;1318:163-70. doi: 10.1016/j.chroma.2013.10.002. Epub 2013 Oct 4.
5
Urinary biomarkers of bladder cancer: an update and future perspectives.
Biomark Med. 2013 Oct;7(5):779-90. doi: 10.2217/bmm.13.73.
6
A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer.
Cancer Lett. 2014 Feb 1;343(1):33-41. doi: 10.1016/j.canlet.2013.09.011. Epub 2013 Sep 14.
7
Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry.
J Proteome Res. 2013 Sep 6;12(9):3865-73. doi: 10.1021/pr4000448. Epub 2013 Aug 7.
8
Distinct metabolic differences between various human cancer and primary cells.
Electrophoresis. 2013 Oct;34(19):2836-47. doi: 10.1002/elps.201300228. Epub 2013 Sep 12.
9
HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease.
J Proteome Res. 2013 Jul 5;12(7):3519-28. doi: 10.1021/pr4004135. Epub 2013 Jun 18.
10
NMR-based metabolomics study of canine bladder cancer.
Biochim Biophys Acta. 2012 Nov;1822(11):1807-14. doi: 10.1016/j.bbadis.2012.08.001. Epub 2012 Aug 8.
Zotero 插件